Common Joint Supplement Glucosamine Linked to Faster Alzheimer's Progression and Higher Death Risk

A Supplement in Millions of Medicine Cabinets Under Scrutiny

More than 40 million Americans take glucosamine — composed of glucose and the amino acid glutamine — each year to slow the breakdown of cartilage in the joints, which may relieve pain and swelling. It's one of those supplements people rarely think twice about. No prescription needed. No doctor visit required. Just a pill from the pharmacy shelf, taken faithfully every morning alongside a multivitamin. But a major new study is raising serious questions about whether that habit could be quietly accelerating one of the most feared diseases in aging.

The study, published June 9 in Nature Metabolism, found that people already showing signs of mild cognitive impairment were 25% more likely to develop dementia if they were taking glucosamine than those who did not use the supplement. Researchers also found that among patients already diagnosed with Alzheimer's disease and related dementias, glucosamine use was associated with a 25% increase in the risk of death. Those are not small numbers — and they're prompting urgent calls for patients and doctors to talk.

What the Research Actually Found

The University of Florida neuroscience research team used artificial intelligence to analyze deidentified health records from the UF Health system spanning 2012 to 2024. Their dataset included approximately 24,000 patients with dementia and 41,000 patients with mild cognitive impairment — a large enough population to generate statistically meaningful associations even after controlling for confounding variables.

They found that a significant proportion — 8% — of both types of patients reported taking glucosamine. After controlling for age, sex, and demographics, the analysis showed that glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia. The researchers didn't stop at patient records. Mice receiving glucosamine showed worsening deficits in social memory — the ability to recognize and remember other individuals. When scientists chemically reduced this sugar-tagging activity, memory performance improved.

The Biology Behind the Warning

Researchers focused on a biological process called glycosylation, in which sugar molecules attach to proteins. It is a normal and essential cellular process, but the researchers found that in the brains of Alzheimer's patients, it appears to occur at unusually high levels — a state they described as hyperglycosylation. Glucosamine, as a sugar-related molecule, appears to feed directly into this dysfunctional pathway in susceptible brains. Researchers noted that glucosamine can cross the blood-brain barrier, where it can contribute to biochemical pathways involved in building complex sugar structures on proteins.

As one expert explained, "hyperglycosylation can greatly increase the brain burden of sugar molecules called N-glycans that overload metabolic processing and disrupt critical cellular processes like synaptic signaling." As these N-glycans accumulate, this leads to destruction of synapses, with the potential to activate the immune system and create a vicious cycle of brain damage. In simpler terms: in a brain already struggling with Alzheimer's, glucosamine may be adding fuel to a fire that's already burning.

What Patients Should Do Now

Although the results do not prove that glucosamine causes dementia and will need to be confirmed in clinical trials, researchers say the work adds to growing evidence that metabolic dysfunction plays an important role in neurodegenerative diseases. That distinction matters. This is an association, not a verdict — but it's a strong enough signal that it shouldn't be ignored, particularly by anyone already experiencing memory concerns.

Experts advise that a growing body of research suggests healthy dietary patterns and balanced nutrition may help support overall brain health, but no single food, beverage, ingredient, vitamin, or supplement has been proven to prevent, treat, or cure Alzheimer's disease or other dementias. The most important takeaway for consumers is to have informed conversations with their healthcare team before starting, stopping, or changing any supplements. The study reveals that hyperglycosylation driven by increased glycan biosynthesis in the brain may significantly contribute to Alzheimer's pathophysiology — and researchers believe this complex metabolic pathway could serve as a novel therapeutic target for the disease. In other words, the same mechanism that makes glucosamine potentially dangerous may also point scientists toward new treatments.